Overview

Price chart · mood · technical indicators

IRWD

Ironwood Pharmaceuticals Incstock Healthcare

Drug Manufacturers - Specialty & Generic

$4.59395.20%Current Market Mood:Strong Bullish

Market Mood

Price Range (1Y)

$0.53$5.78

Current: $4.59

Idea: EMA

1Y Return

+246.7%

Sharpe 3Y

0.64

Market Comparison

vs Healthcare Sector & Drug Manufacturers - Specialty & Generic Industry

IRWD

+395.20%

1Y Performance

Healthcare

Sector 1Y

Drug Manufacturers - Specialty & Generic

Industry 1Y

Fundamentals

Updated daily after market close

P/E ratio29.60Forward 12.33

EPS (TTM)$0.151047.0% YoY

Profit margin8.1%HEALTHCARE

Market cap$730.9MSmall cap

Valuation

Forward P/E: 12.33
PEG ratio: -0.26
P/B: 2.59
P/S (TTM): 2.47
EV/EBITDA: 10.62

Profitability & growth

ROE (TTM): -575.0%
Operating margin: 13.7%
Revenue growth YoY: -47.3%
Dividend yield: —
Beta: 0.17

Last earnings

Feb 12, 2026 · Estimate $0.02 · Reported $-0.01

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Ironwood Pharmaceuticals Inc

Company profile

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. The company is headquartered in Boston, Massachusetts.

Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Exchange: NASDAQ
Country: USA
Currency: USD

Company profile

HQ: 100 SUMMER STREET, BOSTON, MA
Fiscal year end: December
Latest quarter: Dec 31, 2025

Market cap$730.9M

Shares outstanding$164.6M

52W high$5.78

52W low$0.53

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer

Overview

IRWD

Market Comparison

Fundamentals

Valuation

Profitability & growth

News & Sentiment

Ironwood (NASDAQ: IRWD) seeks 10M more equity plan shares in 2026 proxy

Book value per share of Ironwood Pharmaceuticals, Inc. Class A – SWB:I76

Bank of America (NASDAQ: IRWD) reports 6.1% stake in Ironwood Pharmaceuticals

The Vanguard Group (NASDAQ: IRWD) reports zero beneficial ownership after realignment

Sarissa Capital (IRWD) cuts Ironwood stake with 6.7M-share sale, keeps 5.8%

Ironwood Pharmaceuticals director Denner sells $20.5m in shares

Ironwood Pharmaceuticals director Denner sells $20.5m in shares By Investing.com

Sarissa funds trim Ironwood (NASDAQ: IRWD) stake with 6.7M-share sale

Ironwood Pharmaceuticals (IRWD) CFO receives 136,612-share stock grant

Ironwood (NASDAQ: IRWD) CCO granted 136,612 restricted shares as equity award

Ironwood (NASDAQ: IRWD) CEO receives 409,836-share restricted stock award

Ironwood Pharmaceuticals (IRWD) CLO receives 136,612-share RSU grant

Ironwood (IRWD) accounting chief granted 163,934 RSUs in stock award

Ironwood (IRWD) SVP and CMO awarded 136,612-share RSU performance grant

Ironwood (NASDAQ: IRWD) confirms revolving credit facility maturity in 2028

Ironwood Pharmaceuticals, Inc. 8-K SEC Filing Details – Company Information, Address, and Nasdaq Listing

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives Consensus Recommendation of "Hold" from Brokerages

Ironwood Pharmaceuticals (IRWD) Margin Rebound Challenges Bearish Narratives Despite Softer Revenue

[Form 4] IRONWOOD PHARMACEUTICALS INC Insider Trading Activity

Ironwood (NASDAQ: IRWD) chief auto-sells 36,492 shares for tax withholding

About Ironwood Pharmaceuticals Inc

Classification

Company profile

IRWD

Market Comparison

IRWD Market Analysis

Overview

IRWD

Market Comparison

Fundamentals

Valuation

Profitability & growth

News & Sentiment

Ironwood (NASDAQ: IRWD) seeks 10M more equity plan shares in 2026 proxy

Book value per share of Ironwood Pharmaceuticals, Inc. Class A – SWB:I76

Bank of America (NASDAQ: IRWD) reports 6.1% stake in Ironwood Pharmaceuticals

The Vanguard Group (NASDAQ: IRWD) reports zero beneficial ownership after realignment

Sarissa Capital (IRWD) cuts Ironwood stake with 6.7M-share sale, keeps 5.8%

Ironwood Pharmaceuticals director Denner sells $20.5m in shares

Ironwood Pharmaceuticals director Denner sells $20.5m in shares By Investing.com

Sarissa funds trim Ironwood (NASDAQ: IRWD) stake with 6.7M-share sale

Ironwood Pharmaceuticals (IRWD) CFO receives 136,612-share stock grant

Ironwood (NASDAQ: IRWD) CCO granted 136,612 restricted shares as equity award

Ironwood (NASDAQ: IRWD) CEO receives 409,836-share restricted stock award

Ironwood Pharmaceuticals (IRWD) CLO receives 136,612-share RSU grant

Ironwood (IRWD) accounting chief granted 163,934 RSUs in stock award

Ironwood (IRWD) SVP and CMO awarded 136,612-share RSU performance grant

Ironwood (NASDAQ: IRWD) confirms revolving credit facility maturity in 2028

Ironwood Pharmaceuticals, Inc. 8-K SEC Filing Details – Company Information, Address, and Nasdaq Listing

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives Consensus Recommendation of "Hold" from Brokerages

Ironwood Pharmaceuticals (IRWD) Margin Rebound Challenges Bearish Narratives Despite Softer Revenue

[Form 4] IRONWOOD PHARMACEUTICALS INC Insider Trading Activity

Ironwood (NASDAQ: IRWD) chief auto-sells 36,492 shares for tax withholding

About Ironwood Pharmaceuticals Inc

Classification

Company profile

IRWD

Market Comparison